HC Wainwright Has Lowered Expectations for MetaVia (NASDAQ:MTVA) Stock Price

MetaVia (NASDAQ:MTVA) had its target price cut by stock analysts at HC Wainwright from $40.00 to $20.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has a “buy” rating on the stock.

Several other brokerages also recently weighed in on MTVA. Wall Street Zen downgraded shares of MetaVia from a “hold” rating to a “sell” rating in a research note on Saturday, January 31st. Weiss Ratings restated a “sell (d-)” rating on shares of MetaVia in a research note on Monday, December 22nd. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $26.50.

MetaVia Stock Performance

NASDAQ MTVA opened at $1.22 on Friday. The firm has a 50 day simple moving average of $1.81 and a 200-day simple moving average of $6.80. MetaVia has a one year low of $1.21 and a one year high of $23.10. The firm has a market cap of $2.68 million, a price-to-earnings ratio of -0.15 and a beta of 0.33.

Hedge Funds Weigh In On MetaVia

An institutional investor recently bought a new position in MetaVia stock. Virtu Financial LLC bought a new position in shares of MetaVia Inc. (NASDAQ:MTVA) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned approximately 0.14% of MetaVia at the end of the most recent quarter. 1.37% of the stock is currently owned by hedge funds and other institutional investors.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.